TimesSquare Capital Management LLC Raises Position in Vericel Corporation (NASDAQ:VCEL)

TimesSquare Capital Management LLC boosted its position in Vericel Corporation (NASDAQ:VCEL - Free Report) by 3.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 652,465 shares of the biotechnology company's stock after acquiring an additional 20,305 shares during the period. TimesSquare Capital Management LLC owned 1.30% of Vericel worth $29,113,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in VCEL. GF Fund Management CO. LTD. bought a new stake in shares of Vericel in the fourth quarter valued at approximately $57,000. Meeder Asset Management Inc. raised its holdings in Vericel by 8.4% during the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock valued at $129,000 after acquiring an additional 183 shares during the period. GAMMA Investing LLC lifted its position in shares of Vericel by 34.8% during the first quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock worth $129,000 after acquiring an additional 748 shares in the last quarter. Xponance Inc. bought a new position in shares of Vericel in the fourth quarter worth $214,000. Finally, Mackenzie Financial Corp purchased a new position in shares of Vericel in the fourth quarter valued at $215,000.

Vericel Trading Down 0.3%

Shares of Vericel stock traded down $0.11 on Monday, hitting $39.82. 495,931 shares of the company traded hands, compared to its average volume of 475,427. Vericel Corporation has a 12-month low of $37.39 and a 12-month high of $63.00. The firm's 50-day simple moving average is $41.87 and its 200 day simple moving average is $47.43. The company has a market cap of $2.00 billion, a P/E ratio of 1,327.78 and a beta of 1.32.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). Vericel had a net margin of 1.25% and a return on equity of 1.09%. The firm had revenue of $52.60 million for the quarter, compared to analysts' expectations of $53.86 million. During the same quarter in the previous year, the business earned ($0.08) EPS. The company's revenue for the quarter was up 2.6% on a year-over-year basis. Analysts predict that Vericel Corporation will post 0.14 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on VCEL shares. Stephens restated an "overweight" rating and issued a $67.00 target price on shares of Vericel in a research note on Monday, June 16th. Truist Financial cut their price objective on shares of Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Wall Street Zen cut shares of Vericel from a "hold" rating to a "sell" rating in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.